1CARAGLIA M, MARRA M, LEONETTI G, et al. New strategies based on zoledronic acid/tipifarnib combination in the therapy of prostate cancer[ J ]. Bone ,2006,38 ( 3 ) :44.
2YANAMANDRA N, COLACO N M, PARQUET N A,et al. Tipifarnib and bortezomib are synergistic and overcome cell adhesion-mediated drug resistance in multiple myeloma and acute myeloid leukemia [ J ]. Clin Cancer Res,2006,24 ( 19 ) : 3013-3018.
3MEDEIROS B C, LANDAU H J, MORROW M, et al. The farnesyl transferase inhibitor, tipifarnib, is a potent inhibitor of the MDR1 gene product, P-glycoprotein, and demonstrates significant cytotoxic synergism against human leukemia cell lines[ J]. Leukemia,2007, 21 (4) :739-746.
4MARTIN L A, HEAD J E, PANCHOIL S, et al. The farnesyltransferase inhibitor R115777 (tipifamib) in combination with tamoxifen acts synergistically to inhibit MCF-7 breast cancer cell proliferation and cell cycle progression in vitro and in vivo [ J ]. Mol Cancer Ther ,2007,6 ( 9 ) :2458-2467.
5AWADA A,ZHANG S, GLI T,et al. A phase I clinical and pharmacokinetic study of tipifarnib in combination with docetaxel in patients with advanced solid malignancies [ J ]. Curr Med Res Opin ,2007,23 ( 5 ) :991-1003.
6SPARANO J A, MOULDER S, KAZI A, et al. Targeted inhibition of farnesyltransferase in locally advanced breast cancer: a phase I and II trial of tipifarnib plus dose-dense doxorubicin and cyclophosphamide [ J ]. J Clin Oncol,2006,24 ( 19 ) :3013-3018.
7CORTES J, QUINTAS-CARDAMA A, GARCIA-MANERO G, et al. Phase I study of tipifarnib in combination with imatinib for patients with chronic myelogenous leukemia in chronic phase after imatinib failure [ J ]. Cancer, 2007,110 (9) : 2000-2006.
8MOYAL E C, LAPRIE A,DELANNAS M,et al. Phase I trial of tipifamib(Rl15777) concurrent with radiotherapy in patients with glioblastoma muhiforme[ J] lnt J Radiat Oncol Biol Phys,2007, 68 ( 5 ) : 1396-1401.
9TAYLOR S A, MARRINAN C H, LIU G,et al. Combining the farnesyltransferase inhibitor lonafarnib with paclitaxel results in enhanced growth inhibitory effects on human ovarian cancer models in vitro and in vivo [ J ]. Gynecol Oncol,2008,109 ( 1 ) :97-106.
10NEADY N E, LIPTON A,ZHU Y,et al. Phase I study of the farnesyhransferase inhibitor lonafanib with weekly paclitaxel in patients with solid tumors [ J ]. Clin Cancer Res, 2007,13 (2 Pt 1 ) : 576-583.
